Zoetis (NYSE:ZTS – Get Free Report) is expected to issue its quarterly earnings data before the market opens on Thursday, ...

ATLANTA — A pet drug maker is making a big change on their labels for their new arthritis shot after Channel 2 Action News ...

The animal-health company added warnings about side effects such as seizures and paralysis to the label for Librela.

Zoetis Inc. today announced that it has updated the U.S. label for Librela® (bedinvetmab injection), following its submission ...

Librela (bedinvetmab injection) is a monthly injectable monoclonal antibody, for which real-world drug experience data has ...

Zoetis is estimated to be 27% undervalued based on current share price of US$171 Analyst price target for ZTS is US$209 which is 11% below our fair value estimate ...

Zoetis (ZTS) ended the recent trading session at $172.24, demonstrating a +0.17% swing from the preceding day's closing price. This change lagged the S&P 500's 0.72% gain on the day. Elsewhere, the ...

New Jersey-based Zoetis, Inc. is the world’s largest manufacturer of medicine and vaccinations for pets and livestock in the United States and internationally. Its products are complemented by ...

Learn more about whether Sanofi or Zoetis Inc. is a better investment based on AAII's A+ Investor grades, which compare both ...

Zoetis Inc (ZTS) stock saw a modest uptick, ending the day at $171.94 which represents a slight increase of $1.04 or 0.61% from the prior close of $170.9. The stock opened at $169.06 and touched a low ...

Shares of Zoetis Inc. ZTS slid 1.05% to $170.90 Friday, on what proved to be an all-around poor trading session for the stock ...